Surnames can reveal much about your family history, but they can also be a minefield of misinformation. By Paul Blake. Twenty members of the public describe what spurred them on to discover more ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up ...

Of note, Regeneron also revealed on Tuesday that for the first time in the company’s history, it will start offering quarterly dividends at $0.88 per share. The first batch of dividends will be paid ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in ...

Explore the history of the BBC since its foundation in 1922 to the present day Explore more than 100 years of the BBC’s history – click on our interactive timeline or investigate a topical ...

the most surprising aspect of the earnings release was that Regeneron declared a dividend for the first time in its history, of $0.88 per quarter, which translates to an annual yield of ~0.53% - a ...

Regeneron is the second pharma group to sign ... Those can be used for "natural history analysis, trial design, cohort formation, and data analysis," according to the partners.

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported fourth-quarter earnings of $917.7 million. On a per-share basis, the Tarrytown ...

As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.

February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...